David Y. Graham, MD; Yoshio Yamaoka, MD, PhD
Potential Financial Conflicts of Interest: Dr. Graham has received small amounts of grant support and/or free drugs or urea breath tests from Meretek Diagnostics, Janssen/Eisai, TAP Pharmaceuticals, and Biohit for investigator-initiated and investigator-controlled research in the area of H. pylori infection. He is a paid consultant for Otsuka Pharmaceuticals; a member of the Board of Directors of Meretek Diagnostics, the manufacturer of the 13C-urea breath test; and a consultant to Novartis with regard to H. pylori vaccine development. Finally, he receives royalties on the Baylor College of Medicine patent covering the serologic test HM-CAP (E-Z-EM, Lake Success, New York).
Graham DY, Yamaoka Y. Ethical Considerations of Comparing Sequential and Traditional Anti–Helicobacter pylori Therapy. Ann Intern Med. 2007;147:434-435. doi: 10.7326/0003-4819-147-6-200709180-00022
Download citation file:
Published: Ann Intern Med. 2007;147(6):434-435.
TO THE EDITOR:
Vaira and colleagues (1) recently reported that a sequential therapy regimen led to high cure rates and was better than legacy triple therapy (proton-pump inhibitor, amoxicillin, and clarithromycin) for eradicating Helicobacter pylori infection in Italian patients with dyspepsia or peptic ulcers. The sequential regimen was much more effective than triple therapy among patients with clarithromycin-resistant bacteria (1). These investigators and others have compared identical or very similar regimens and have reported similar high cure rates (Figure[2–6]).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only